JP Morgan Chase
DMTX

JP Morgan Chase’s Dimension Therapeutics, Inc DMTX Stock Holding History

JP Morgan Chase’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,713
Closed -$16K – 5430
2017
Q2 		$16K Sell
10,713
-13,273
-55% -$18K ﹤0.01% 4586
2017
Q1 		$42K Sell
23,986
-87,673
-79% -$233K ﹤0.01% 4576
2016
Q4 		$486K Buy
111,659
+23,434
+27% +$125K ﹤0.01% 3786
2016
Q3 		$705K Sell
88,225
-103,650
-54% -$749K ﹤0.01% 3283
2016
Q2 		$1.15M Sell
191,875
-47,125
-20% -$359K ﹤0.01% 3103
2016
Q1 		$1.87M Buy
239,000
+80,200
+51% +$632K ﹤0.01% 2738
2015
Q4 		$1.79M Buy
+158,800
New +$2.01M ﹤0.01% 2812

Other funds holding DMTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

JP Morgan Chase's DMTX Position: Q3 2017 in Review

JP Morgan Chase sold out of Dimension Therapeutics, Inc (DMTX) in Q3 2017, closing a stake of 10,713 shares — an estimated $16K sold.

JP Morgan Chase first reported a position in DMTX in Q4 2015 and held it in 7 quarters. The position peaked at $1.87M in Q1 2016. 34 funds tracked by Wall St. Rank hold DMTX as of Q3 2017.

  • JP Morgan Chase reported no remaining Dimension Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
  • JP Morgan Chase sold 10,713 Dimension Therapeutics, Inc shares in Q3 2017, an estimated $16K.
  • JP Morgan Chase first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 7 quarters.
  • JP Morgan Chase's Dimension Therapeutics, Inc position peaked at $1.87M in Q1 2016.
  • 34 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q3 2017.

Based on JP Morgan Chase's 13F filing for Q3 2017, filed 9 Nov 2017.